ConvexiaYC S25 landing page report.
← Back to YC S25

Your landing page’s weakest score is Trust.

Fix Trust

Score over time

8070605040BenchSci 55 on Apr 21 (Wayback)BenchSci 52 on May 16 (Wayback)BenchSci 66 on Aug 5 (Wayback)BenchSci 63 on Sep 22 (Live)Insilico Medicine 54 on Jun 16 (Wayback)Insilico Medicine 55 on Jun 27 (Wayback)Insilico Medicine 56 on Jul 15 (Wayback)Insilico Medicine 56 on Jul 26 (Wayback)Insilico Medicine 56 on Aug 10 (Wayback)Insilico Medicine 57 on Sep 9 (Wayback)Insilico Medicine 54 on Sep 22 (Live)Iambic Therapeutics 54 on Apr 27 (Wayback)Iambic Therapeutics 55 on May 10 (Wayback)Iambic Therapeutics 56 on May 21 (Wayback)Iambic Therapeutics 56 on Jun 7 (Wayback)Iambic Therapeutics 55 on Jul 11 (Wayback)Iambic Therapeutics 57 on Sep 4 (Wayback)Iambic Therapeutics 52 on Sep 20 (Live)Recursion 63 on Jun 26 (Wayback)Recursion 62 on Jul 7 (Wayback)Recursion 64 on Jul 22 (Wayback)Recursion 50 on Aug 10 (Wayback)Recursion 50 on Aug 27 (Wayback)Recursion 53 on Sep 11 (Wayback)Recursion 66 on Sep 20 (Live)Cradle 60 on Apr 16 (Wayback)Cradle 61 on May 7 (Wayback)Cradle 65 on May 19 (Wayback)Cradle 67 on Aug 4 (Wayback)Cradle 70 on Sep 2 (Wayback)Cradle 74 on Sep 22 (Live)Convexia 67 on Apr 16 (Wayback)Convexia 66 on Sep 22 (Live)Apr 16Sep 22
Past reportsShow past reportsHide past reports
  1. Sep 22, 202666LiveOverall −1 · Trust −4 · Information hierarchy −2Viewing
  2. Apr 16, 202667First tracked report — strongest Information hierarchy 78, weakest Trust 42View →

Trust

38Poor

Proof that the product is real, competent, and safe to try.

Convexia
Insilico Medicine
Cradle
Recursion
BenchSci
Trust read
Convexia"Free to try. No credit card." next to the Test the Agents CTA
BenchSci"Trusted by world class teams" section heading peeking at the bottom of the desktop fold
Insilico MedicinePipeline table rows showing "Out-licensed to Exelixis" and "Out-licensed to Menarini" with Phase I–III progress bars and
Iambic TherapeuticsNo visible trust signal identified.
RecursionUnlocking the First Neuroscience Target for the Recursion and Genentech Collaboration
CradleNews bar: "Lundbeck partners with Cradle to discover and optimize brain disorder treatments"

Value props

62Fair

Title, subtitle, hero — do they sell the product's true value?

Convexia’s headline undersellsUncover Drug Assets 10x fasterFind and evaluate drugs better than ever before.

Working

  • 10x claim quantifies the speed benefit
  • Names the audience's job: drug assets
  • "Free to try. No credit card." lowers risk

Could improve

  • Subhead is a generic abstraction
  • Hero image decorates, shows no product
  • No proof of how agents deliver 10x

Information hierarchy

76Fair

Does the design help or inhibit what the page is trying to say?

Information hierarchy annotations on the desktop capture123
  1. Login button styling — Styled in the same green pill weight as "Test the Agents", making the fold's strongest visual competitor an exit path.
  2. Test the Agents CTA — Small footprint far below a huge headline; it reads lighter than the nav's Login pill and sits low in the scan path.
  3. Hero background bubbles — Abstract dark blobs fill the right half without communicating drug discovery, leaving the fold's visual story generic.

Mobile web

76Fair

The phone experience as a first-class citizen.

Mobile web annotations on the mobile capture12
  1. Test the Agents CTA — Desktop-proportioned half-width button; should be near-full-bleed for the thumb.
  2. Free to try text — Reassurance copy crammed beside the CTA instead of stacked below it.

CTA

78Fair

Copy, size, verb, cost-feel — does the primary CTA earn the click?

Convexia
BenchSci

Problems

  • 'free' sits beside, not on, button
  • small footprint vs huge headline